Repositioning Candidate Details
| Candidate ID: | R0971 |
| Source ID: | DB06281 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Torcetrapib |
| Synonyms: | Torcetrapib |
| Molecular Formula: | C26H25F9N2O4 |
| SMILES: | CCOC(=O)N1[C@H](CC)C[C@H](N(CC2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)C(=O)OC)C2=C1C=CC(=C2)C(F)(F)F |
| Structure: |
|
| DrugBank Description: | Torcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination of atorvastatin and the study drug. |
| CAS Number: | 262352-17-0 |
| Molecular Weight: | 600.4733 |
| DrugBank Indication: | Investigated for use/treatment in peripheral vascular disease and hyperlipidemia. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Torcetrapib is an inhibitor of cholesteryl ester-transfer protein (CETP) that increases high-density lipoprotein (HDL) cholesterol levels. The drug increases HDL-cholesterol and apolipoprotein A-I levels and decreases LDL-cholesterol and apolipoprotein B levels. The effect is showed in monotherapy and when administered in combination with statins. |
| Targets: | Cholesteryl ester transfer protein antagonist |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|